ACXP - CIK 0001736243
Acurx Pharmaceuticals, Inc. has filed 232 documents with the SEC between 2018 and 2026. The most frequent type is insider trade (51 filings), alongside the regular cadence of annual reports, quarterly reports, and event disclosures every public company must make. Use the filters to focus on one filing type, or flip the sort to trace the company's history from its earliest paperwork.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Filing | Type | Filed | Period covered |
|---|---|---|---|
| Insider trade | 4 | 2024-06-18 | 2024-06-17 |
| Insider trade | 4 | 2024-06-18 | 2024-06-17 |
| Insider trade | 4 | 2024-06-18 | 2024-06-17 |
| Major company event | 8-K | 2024-06-17 | 2024-06-17 |
| Major company event | 8-K | 2024-05-15 | 2024-05-15 |
| Quarterly report | 10-Q | 2024-05-14 | 2024-03-31 |
| Annual report to shareholders | ARS | 2024-04-29 | 2023-12-31 |
| Proxy materials | DEFA14A | 2024-04-29 | - |
| Proxy statement | DEF 14A | 2024-04-29 | 2024-06-17 |
| RW | - | 2024-04-17 | - |
| Insider trade | 4 | 2024-04-03 | 2024-02-23 |
| Insider trade | 4 | 2024-04-03 | 2024-02-23 |
| Insider trade | 4 | 2024-04-03 | 2024-02-23 |
| Free writing prospectus | FWP | 2024-04-02 | - |
| S-1/A | - | 2024-03-29 | - |
| Major company event | 8-K | 2024-03-18 | 2024-03-18 |
| IPO registration | S-1 | 2024-03-18 | - |
| Annual report | 10-K | 2024-03-15 | 2023-12-31 |
| Employee stock plan | S-8 | 2024-03-15 | - |
| Passive ownership stake (update) | SC 13G/A | 2024-02-14 | - |
| Insider trade | 4 | 2024-01-22 | 2024-01-19 |
| Insider trade | 4 | 2024-01-04 | 2021-12-02 |
| Insider trade | 4 | 2024-01-04 | 2024-01-03 |
| Major company event | 8-K | 2023-11-15 | 2023-11-15 |
| Prospectus supplement | 424B5 | 2023-11-15 | - |
| Major company event | 8-K | 2023-11-14 | 2023-11-14 |
| Quarterly report | 10-Q | 2023-11-13 | 2023-09-30 |
| Major company event | 8-K | 2023-11-03 | 2023-11-02 |
| Major company event | 8-K | 2023-10-02 | 2023-10-02 |
| Major company event | 8-K | 2023-08-14 | 2023-08-14 |
| Quarterly report | 10-Q | 2023-08-11 | 2023-06-30 |
| 424B3 | - | 2023-07-13 | - |
| EFFECT | - | 2023-07-10 | - |
| Company correspondence | CORRESP | 2023-07-06 | - |
| SEC correspondence | UPLOAD | 2023-07-05 | - |
| IPO registration | S-1 | 2023-06-29 | - |
| Major company event | 8-K | 2023-06-20 | 2023-06-15 |
| Insider trade | 4 | 2023-06-16 | 2023-06-15 |
| Insider trade | 4 | 2023-06-16 | 2023-06-15 |
| Insider trade | 4 | 2023-06-16 | 2023-06-15 |
| Insider trade | 4 | 2023-06-16 | 2023-06-15 |
| Insider trade | 4 | 2023-06-16 | 2023-06-15 |
| 424B3 | - | 2023-05-18 | - |
| Prospectus supplement | 424B5 | 2023-05-17 | - |
| Major company event | 8-K | 2023-05-17 | 2023-05-16 |
| Quarterly report | 10-Q | 2023-05-12 | 2023-03-31 |
| Annual report to shareholders | ARS | 2023-04-27 | 2022-12-31 |
| Proxy materials | DEFA14A | 2023-04-27 | - |
| Proxy statement | DEF 14A | 2023-04-27 | 2023-06-15 |
| PRE 14A | - | 2023-04-17 | 2023-06-15 |